Rexahn Pharmaceuticals, Inc. Awarded Qualifying Therapeutic Discovery Project Grants to Further Develop Anti-Cancer, Depression, and Erectile Dysfunction Treatments

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced today that it has been awarded grants totaling $822,137 through the US Federal Government’s Qualifying Therapeutic Discovery Project.
MORE ON THIS TOPIC